In vitro susceptibility of enterococci strains isolated from urine samples to fosfomycin and other antibiotics

Butcu, Mehmet; Şenbayrak, Seniha; İnan, Asuman; Aksaray, Sebahat; Engin, Derya Öztürk; Calisici, Gulcin

doi:10.1007/s10156-011-0212-7

Cited by 30 publications

(22 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 In a study carried out in Turkey, fosfomycin resistance was not determined in VRE isolates, similar to the results of our study. 18 MRSA is considered an important problem in both hospital-and community-acquired infections. 19 In a study conducted by Falagas et al, 20 129 of 130 (99.2%) MRSA isolates and 745 of 961 (77.5%) MRCoNS isolates were susceptible to fosfomycin.…”

Section: 13mentioning

confidence: 99%

In vitro efficacy of fosfomycin against clinical strains

Karadağ¹

2014

Jmid

View full text Add to dashboard Cite

Objective: Fosfomycin is an alternative drug for treatment of uncomplicated urinary tract infections. This study aimed to investigate in vitro activity of fosfomycin against methicillin-resistant Staphylococcus aureus (MRSA), methicillinresistant coagulase negative staphylococci (MRCoNS), vancomycin-resistant Enterococcus faecium (VR E. faecium), Escherichia coli, Klebsiella pneumoniae, and Enterobacter isolates. Methods:Clinical isolates of MRSA, MRCoNS, E. coli, K. pneumoniae and Enterobacter spp. and VRE isolates which were isolated from rectal swaps were identified with Vitek 2 Compact (Biomeriux, France) and BD Phoenix (BD USA) automated systems. The Kirby-Bauer disc diffusion method was used to determine the susceptibility to fosfomycin.Results: All the MRSA (n=40), MRCoNS (n=40), and VR E. faecium (n=62) isolates were susceptible to fosfomycin. The fosfomycin susceptibility rates for E. coli, K. pneumoniae, and Enterobacter spp. were 97.5% (39 of 40), 97.3% (36 of 37), and 86.9% (20 of 23), respectively. One (2.7%) isolate of K. pneumoniae and three (13.1%) isolates of Enterobacter spp. showed intermediate susceptibility to fosfomycin. Resistance to fosfomycin was detected in only one (2.5%) isolate of E. coli. Conclusion:Based on the results of our study, fosfomycin is highly active against a collection of several gram-positive and gram-negative bacteria, including multidrug resistant isolates, and is an alternative drug in the treatment option.

show abstract

Section: 13mentioning

confidence: 99%

In vitro efficacy of fosfomycin against clinical strains

Karadağ¹

2014

Jmid

View full text Add to dashboard Cite

show abstract

“…[2,4] Thus, there is a need for less expensive and effective alternative antibiotics for the treatment of VRE and ESBL UTIs. [5][6][7][8][9] Fosfomycin tromethamine is a synthetic, broad spectrum, bactericidal antibiotic that works by inhibiting pyruvyl transferase during bacterial cell wall synthesis, and it may also decreases bacterial adherence to epithelial cells in the urinary tract. [10] Fosfomycin is available as an orally administered single-dose 3 gram sachet that is mixed with water.…”

Section: Introductionmentioning

confidence: 99%

“…[11] Fosfomycin has demonstrated efficacy in both in vitro and in vivo studies for treating UTIs caused by ESBL-producing Enterobacteriaceae, [12][13][14][15] while in vitro studies have shown high susceptibility of VRE to fosfomycin with susceptibilities of 98%. [5][6][7] Clinical data are limited to bolster the use of fosfomycin; however, a recent study showed high microbiological cure rates and in vitro susceptibility of VRE and ESBL UTI isolates to fosfomycin. [16] In 2010, the University of Michigan Health System (UMHS) Antimicrobial Stewardship Program introduced a guideline recommending the use of fosfomycin tromethamine for the treatment of lower UTIs caused by VRE or ESBL producing organisms that are resistant to other oral antibiotics.…”

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy of Fosfomycin for the Treatment of Complicated Lower Tract and Uncomplicated Urinary Tract Infections

Nagel

Washer²,

Kunapuli³

et al. 2015

Int Arch Med

View full text Add to dashboard Cite

Fosfomycin is an oral antibiotic with activity against multidrug resistant organisms, including vancomycin-resistant enterococcus (VRE) and extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae. However, there is currently no information describing efficacy of fosfomycin compared to other agents for healthcare associated UTIs. Additionally, there is minimal information characterizing the potential cost savings with utilization of fosfomcyin versus traditional therapies. This retrospective study evaluated clinical and economic outcomes of fosfomycin compared to matched controls. The controls were before the addition of fosfomycin to hospital formulary with recommended prescribing criteria. The fosfomycin group consisted of patients who were admitted to the hospital after the addition of fosfomycin to the hospital formulary with recommended prescribing criteria. Patients receiving fosfomycin for the treatment of UTI were matched to control patients based on pathogen, renal function, and presence of a lower UTI. A total of 86 patients were evaluated. The majority of patients received fosfomycin for the treatment of VRE (45.6%) and ESBL producing Enterbacteriaceae (16.3%) UTIs. Patients with a combination of allergies or documented resistance to first line agents also received fosfomycin to treat Enterococcus (25.6%), Enterobacteriaceae (7.8%), or polymicrobial UTIs (4.7%). Doxycycline, nitrofurantoin, sulfamethoxazole/trimethoprim, meropenem, and linezolid were the most common antibiotics prescribed in the control group. The average days of treatment were lower in the fosfomycin group (2.93 vs. 7.19 days, p<0.0001). Fosfomcyin was associated with similar clinical success rates (95 vs. 95%, p>0.99) and recurrence rates (4.7 vs. 4.7%, p>0.99).

show abstract

“…These infections also carry the risk of possible progression to bacteremia. The empirical choice of an effective treatment is becoming more difficult as urinary pathogens are increasingly becoming resistant to commonly used antibiotics (Nicolle et al, 1996;Barret et al, 1999;Mathai et al, 2001;Karlowsky et al, 2001;Ishaq et al, 2011;Dharmadhikari and Peshwe, 2009;Butcu et al, 2011;Ultley et al, 1988;Leclerq et al, 1988;Ishaq et al, 2011). Any infection left untreated like UTI, kidney infection, is extremely dangerous and can lead to life threatening conditions such as bacteremia.…”

Section: Introductionmentioning

confidence: 99%

Rapid Real Time PCR Based Detection of Cell Count in Case of Urinary Tract Infection

Nandy

Thakur

Chaudhuri

2013

American Journal of Biochemistry and Biotechnology

View full text Add to dashboard Cite

Microbial identification and antimicrobial susceptibility testing methods currently used in clinical microbiology laboratories require at least two to three days because they rely on the growth and isolation of micro-organisms. This long, but necessary, delay has enormous consequences on prophylactic usage of antimicrobial drugs. This study was an attempt to reduce this detection time span. Taq Man Real Time PCR has been used as an important tool in the differentiation of Gram nature of bacteria present in UTI patients that allows detection of spiked bacterial 16S rDNA from urine samples within a short span of 5h and also gives us the corresponding cell count of both/either Gram positive and negative organisms present. A standard curve was generated which was used to determine the cell count of control as well as patient samples. Detection could be done in the range of 10 3 to 10 6 cells/mL Patient samples screened clustered either in the allele 1 or allele 2 axes, depending on majority concentration of Gram nature of the microorganisms. The cell counts for control individuals were scattered within 0 to 10 2 , while very few in the range of 10 4 . The case was just reverse for patient group, where most of the points were scattered within 10 4 to 10 8 . Thus the optimal selection of appropriate antimicrobials (depending on the gram nature) by clinicians, will be gradually improved as an increasing number of rapid molecular diagnostic tools for the detection, identification and characterization of infectious agents become commercially available.

show abstract

In vitro susceptibility of enterococci strains isolated from urine samples to fosfomycin and other antibiotics

Cited by 30 publications

References 13 publications

In vitro efficacy of fosfomycin against clinical strains

In vitro efficacy of fosfomycin against clinical strains

Clinical Efficacy of Fosfomycin for the Treatment of Complicated Lower Tract and Uncomplicated Urinary Tract Infections

Rapid Real Time PCR Based Detection of Cell Count in Case of Urinary Tract Infection

Contact Info

Product

Resources

About